News

Patients with moderate to severe atopic dermatitis (AD)-or eczema-may be successfully treated using a rheumatoid arthritis (RA) drug recently shown to reverse 2 other skin conditions, vitiligo and alopecia areata, according to findings published early online in the Journal of the American Academy of Dermatology.

Phoenix Children's Hospital's leadership team looked at how the foundational practices of accountable care could be implemented at the pediatric level. Here's what they found.

In this blog response to the July 13 article "5 reasons to keep biosimilar names the same," Louis Tharp, executive director or Global Healthy Living Foundation, lists 5 reasons biosimilars must have distinguishable names.

Recent reports suggest that many urgent care and primary care visits could be conducted as a virtual consult.

"The Express Scripts Exchange Pulse" report compares prescription medication use among exchange plan enrollees to those who are enrolled in a traditional health plan benefit.

On July 7, the FDA updated its list of drugs that are in short supply. Some of the drugs – such as Sodium Chloride 0.9 percent Injection Bags – have been in short supply for months, while others have become more problematic recently.

The FDA last week approved Rexulti (brexpiprazole) for schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).

In this blog post, Robert Kyle of AdverseEvents compares the results of a postmarket survey of 3 obesity drugs.

Major safety concerns exist for many top-selling prescription drugs including benzodiazepines/prescription sleep aids, anticoagulants, cholesterol-lowering statins, oxycodone and hydrocodone, and stimulants. The following provides an overview of these classes and issues.

FDA is warning that diazoxide (Proglycem) for low blood sugar has caused pulmonary hypertension (high pressure in the blood vessels leading to the lungs) in infants and newborns.

FDA’s approval last week of AstraZeneca's Iressa (gefitinib) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) is an important tool in fighting the disease.

FDA approved Ipsen Biopharmaceuticals’ supplemental Biologics License Application (sBLA) for abobotulinumtoxinA (Dysport) for the treatment of upper limb spasticity (ULS).

The U.S. Department of Health and Human Services (HHS) will investigate how much money Medicaid has lost over the past decade paying for rising generic drug prices by comparing price increases between 2005 and 2014 against the rate of inflation.

A recent survey by FAIR Health, an independent, not-for-profit dedicated to healthcare cost and insurance transparency, indicates the top factors that influence consumers' health plan selection.

A recent survey by KPMG identifies key challenges many organizations face in preparing for value-based reimbursement.

At the recent Midas+ Annual Symposium, C-level healthcare executives were asked about their perspective on population health management. Here's what they said.

Cybersecurity breaches are hitting the healthcare industry hard. Here are 10 recent victims.

Here are four ways to help your organization overcome key hurdles to effective patient communication.

A recent report claims that many insurers are failing to comply with ACA coverage requirements. Here are some of the key requirements to pay attention to.

The Healthcare Supply Chain Association (HSCA), the Generic Pharmaceutical Association (GPhA), and other healthcare stakeholders are calling on FDA to institute a clear policy for biologics and biosimilars.

In this commentary, three pharmacy experts explain why they believe the 340B Drug Program is a needed safety net for safety net hospitals.

Reducing hospital-acquired infections has become a top priority for hospitals in the face of new penalties from CMS.

Patient-centered pharmacies, which put consumers and their relationship with pharmacists and caregivers at the center of the business model, is producing improved outcomes.

Clinical Decision Support (CDS) tools are improving outcomes for patients across the country.

Actavis is voluntarily recalling more than half a million boxes of Lutera birth control pills because of packaging problems.

The FDA this week approved Novartis’s sacubitril/valsartan (Entresto) tablets to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction (HFrEF).

Stuart M. Gerson explains how Chief Justice John Roberts came to his conclusion in King v. Burwell and how subsidies will affect the healthcare industry.